A few more points of note from the Annual Report
TPM/Daptomycin
Rapid pathway to file determined…..
An initial plan for advancing TPM®/Daptomycin as rapidly as possible towards filing has been developed and will form the basis for work on the asset in 2019. TPM®/Daptomycin has strong commercial potential and is Phosphagenics’ most advanced injectable asset. Its progression will be prioritised in 2019.
Licensing
It is anticipated that a range of licensing opportunities for pharmaceutical products containing TPM® will be announced in the coming months.
Animal Health and Nutrition
Registered product for species “yet to be disclosed” - 1st generation formulation development
Management departure
Alex Stojanovic was made redundant on 30 September 2018.
A few more points of note from the Annual Report TPM/Daptomycin...
Add POH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| POH (ASX) Chart |
Day chart unavailable
